Navigation Links
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Date:12/13/2007

Oral Presentation of the US Oncology Adjuvant Trial 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and Cyclophosphamide

Improved Overall Survival Versus An Anthracycline Combination

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Results presented at the 30th annual San Antonio Breast Cancer Symposium (SABCS) showed that for women with early stage breast cancer who have had surgery, treatment with the investigational chemotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. The presentation reports results with a median follow-up of seven years and has been updated since the last report was published with 5.5 years median follow-up [Jones S et al. J Clin Oncol, 2006, 24:5381-7]. This latest report has also been updated from the abstract submitted to SABCS 2007.

In the updated analysis, overall survival at seven years was statistically higher among women treated with Taxotere(R) and cyclophosphamide (TC) versus those treated with doxorubicin and cyclophosphamide (AC): 87% versus 82% (HR: 0.69, [95% CI, 0.50, 0.97]). The 31% reduction in the risk of death was statistically significant (p=0.032). At seven years, the disease-free survival (DFS) was also statistically greater among women treated with TC than those treated with AC: 81% versus 75% (HR: 0.74, [95% CI, 0.56, 0.98]). The 26% reduction in the risk of cancer recurrence among women treated with TC was statistically significant (p=0.033). The disease-free survival benefit seen in the elderly patients (aged 65 years or older; 31% risk reduction of recurrence) is consistent with that in the overall patient population.

Principal study investigator Dr. Stephen Jones, medical director and co-chair, breast cancer research committee of US Oncology, helped develop the regimen combining the anthracycline doxorubicin with cyclophosphamide, which became a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
2. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
3. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
4. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
5. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
6. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
9. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
10. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
11. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... SOUTH SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that Jerry McMahon, Ph.D., ... in early September: The Thomas Weisel Partners ... p.m. Eastern time at the Four Seasons Hotel ...
... Aug. 27 Sanofi-aventis,U.S. launched today a new ... (oxaliplatin injection) for patients who have,adjuvant stage III ... to offer more convenience, efficiency and safety in ... had been,available in 50 mg and 100 mg ...
... Diabetes Meta-Database to Quantify Competitive Treatment Landscape and Accelerate ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin Board: ... clinical drug development, today,announced that it has licensed its public-source ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3
(Date:7/10/2014)... teens living with a cardiac pacemaker, a low sense ... life, reports a study in the July ... official journal of the Society for Developmental and ... Lippincott Williams & Wilkins , a part of ... as a protective factor against lower health-related quality of ...
(Date:7/10/2014)... used to control everyday household items such as washing ... for conservation, a new study has claimed., As part ... scientists and mathematicians, including those from the University of ... engineering, could be replicated in the natural world to ... ,integral control, - in essence a built-in feedback control ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an orange-colored ... carotenoid (alpha- and beta-carotene) absorption and conversion of these ... to new research (1) published in The ... A is involved in reproductive health and growth promotion; ... has antioxidant properties. Provitamin A carotenoids, like alpha- and ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to further his work on a discovery that plays ... Bacterial pneumonia is an important clinical problem and defense mechanisms ...
... a first-of-its-kind cloth that releases nitric oxide gas an ... a wrap to help preserve organs harvested for transplantation. The ... bi-weekly journal. Kenneth Balkus and Harvey Liu note in ... flow and regulates a range of other body functions. Scientists ...
... drugs are embracing new tactics to deal with an ... far from being won. That,s the focus of an ... Engineering News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys ... to identify their products as genuine. C&EN Associate ...
Cached Biology News:LSUHSC awarded multi-million dollar grant to reduce pneumonia 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: